Nexentis Technologies Inc.

Nexentis Technologies experienced sharp trading volatility after its biotechnology subsidiary MitoCareX Bio completed a broad structural assessment of human Solute Carrier transport proteins, a milestone that could broaden its small-molecule drug discovery platform. The stock initially surged as much as 30% before reversing course and trading about 2% lower later in the session. The analysis identified additional SLC proteins outside the SLC25 family whose amino acid structures appear compatible with MitoCareX's proprietary MITOLINE technology, prompting plans to investigate whether MITOLINE-generated 3D models can be used in virtual screening for non-mitochondrial SLC targets. Chief Executive Officer David Palach said the findings demonstrate the flexibility and potential of the MITOLINE platform and the company's ability to identify additional transporter targets. Nexentis also invests in solar energy projects through a Ready-to-Build development model, providing exposure to both healthcare innovation and renewable energy infrastructure.